



Draft Genome Sequence of Rifamycin Derivatives Producing Amycolatopsis mediterranei Strain DSM 46096/S955

Priya Singh, Rashmi Kumari, Udita Mukherjee, Anjali Saxena, Utkarsh Sood, Rup Lal

Department of Zoology, University of Delhi, Delhi, India

Amycolatopsis mediterranei DSM 46096 produces antibiotics of the rifamycin family, 27-demethoxy-27-hydroxyrifamycin B, 25-desacetyl-27-demethoxy-27-hydroxyrifamycin, and 27-demethoxy-27-hydroxyrifamycin SV, which are effective against Gram-negative bacteria. Here, we present the draft genome of *A. mediterranei* 46096 (approx. 10.2 Mbp) having 104 contigs with a GC content of 71.3% and 9,382 coding sequences.

Received 25 July 2014 Accepted 28 July 2014 Published 14 August 2014

Citation Singh P, Kumari R, Mukherjee U, Saxena A, Sood U, Lal R. 2014. Draft genome sequence of rifamycin derivatives producing *Amycolatopsis mediterranei* strain DSM 46096/S955. Genome Announc. 2(4):e00837-14. doi:10.1128/genomeA.00837-14.

Copyright © 2014 Singh et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 3.0 Unported license. Address correspondence to Rup Lal, ruplal@gmail.com.

ifamycins are produced commercially by several strains of Amycolatopsis mediterranei. Semisynthetic derivatives of rifamycin are used for curing tuberculosis and leprosy. There is ambiguity about the origin of these strains, which moved from one industry to another during the past 50 years. In an attempt to further analyze these strains we initially did the taxonomical characterization (1) and then sequenced the genomes of A. mediterranei S699 (2), 46095 (3), and 40773 (4). One strain of A. mediterranei that originated during mutagenesis of wildtype A. mediterranei 43304 (ME/83) (5) with N-methyl-Nnitro-N-nitrosoguanidine at Lepetit laboratory, is A. mediterranei 46096. Its significance lies in its ability to produce antibiotics of the rifamycin family, 27-demethoxy-27hydroxyrifamycin SV, 27-demethoxy-27-hydroxyrifamycin B, and 25-desacetyl-27-demethoxy-27-hydroxyrifamycin, which are effective against Gram-negative bacteria (6).

Due to the severe problem of tuberculosis and the need for the production of analogues of rifamycin, there is a renewed interest in research on *A. mediterranei*. While during the past 30 years emphasis has been on the development of cloning vectors and a transformation system for this group of organisms (7–11) and on the characterization of the *rif*PKS gene cluster (12–14), the genomes of some of strains, including S699 (2), 46095 (3), 40773 (4), U32 (15), and RB (CP003777), have recently been sequenced. We report here the draft genome sequence of *A. mediterranei* 46096.

A. mediterranei 46096 genomic DNA was sequenced by Illumina Genome Analyzer IIx, which generated approximately 2.3 Gb of data (500 bp and 2 kb paired-end libraries) using a PCR-free approach. Sequence coverage of more than $100 \times$ was obtained, corresponding to 25,763,590 pair-end reads. Raw reads were assembled into contigs (n=104, >500 bp) using ABySS software version 1.3.5 (16), set at a k-mer length of 63. The assembled genome had N_{50} value of 462 kb and an average GC content of 71.3%. The draft genome was annotated using RAST version 4.0 (17) and NCBI Prokaryotic Genome Annotation

Pipeline (PGAP) version 2.1 (http://www.ncbi.nlm.nih.gov /genomes/static/Pipeline.html), which identified 9,382 proteincoding genes and 24 pseudogenes. Using PGAP annotations, 15 rRNA and 52 tRNA genes were also predicted. Using antiSMASH (Antibiotic and Secondary Metabolites Analysis Shell) (18), 37 secondary metabolite gene clusters were found that encode 7 type I and II polyketide synthases (PKS), 12 nonribosomal peptide synthetases (NRPSs), 2 NRPS/PKS, lantipeptides, bacteriocin, etc. The rifPKS gene cluster was identical to the earlier reported rifPKS (12), except for the rifB gene, which was 99% similar. Additionally, one CRISPR element and 1,212 tandem repeats were also identified in the draft genome. Average nucleotide identity (ANI) (19) revealed that A. mediterranei 46096 is highly similar to A. mediterranei U32 (99.9%) (15), S699 (99.9%) (2), RB (CP003777), and 40773 (approx. 99.9%) (4) but substantially differs from 46095 (approx. 92.5%) (3).

With the availability of the genome sequences of the abovementioned strains of *A. mediterranei*, including DSM 46096, comparative genomics studies are now under way to better understand the variations in polyketide synthase gene clusters and related genome characteristics. The analysis will further resolve the issue of origin of these strains hitherto unknown and to perform combinatorial biosynthesis for the production of rifamycin analogues (20).

Nucleotide sequence accession numbers. The draft genome sequence of *A. mediterranei* DSM 46096 is available in GenBank database under accession number JMQG00000000. The version described in this paper is JMQG01000000.

ACKNOWLEDGMENTS

The work was supported by grants from the Department of Biotechnology (DBT), Government of India, and the University of Delhi, Department of Science and Technology Promotion of University Research and Scientific Excellence under DU-DST-PURSE. This paper was partly written during the visit by R.L. under the DST-DAAD project to Germany (Helmholtz Zentrum für Umweltzforschung-UFZ, Leipzig). P.S., R.K., U.M., and A.S.

gratefully acknowledge the University Grants Commission (UGC), New Delhi, for providing research fellowships.

REFERENCES

- Bala S, Khanna R, Dadhwal M, Prabagaran SR, Shivaji S, Cullum J, Lal R. 2004. Reclassification of *Amycolatopsis mediterranei* DSM 46095 as *Amycolatopsis* rifamycinica sp. nov. Int. J. Syst. Evol. Microbiol. 54: 1145–1149. http://dx.doi.org/10.1099/ijs.0.02901-0.
- 2. Verma M, Kaur J, Kumar M, Kumari K, Saxena A, Anand S, Nigam A, Ravi V, Raghuvanshi S, Khurana P, Tyagi AK, Khurana JP, Lal R. 2011. Whole genome sequence of the rifamycin B-producing strain *Amycolatopsis mediterranei* S699. J. Bacteriol. 193:5562–5563. http://dx.doi.org/10.1128/JB.05819-11.
- 3. Saxena A, Kumari R, Mukherjee U, Singh P, Lal R. 2014. Draft genome sequence of rifamycin producer *Amycolatopsis* rifamycinica DSM 46095. Genome Announc. 2(4):e00662-14. http://dx.doi.org/10.1128/genomeA.00662-14.
- 4. Mukherjee U, Saxena A, Kumari R, Singh P, Lal R. 2014. Draft genome sequence of *Amycolatopsis mediterranei* DSM 40773, a tangible antibiotic producer. Genome Announc. 2(4):e00752-14. http://dx.doi.org/10.1128/genomeA.00752-14.
- Margalith P, Beretta G. 1960. Rifomycin, XI: taxonomic study on Streptomyces mediterranei nov. sp. Mycopathol. Mycol. Appl. 4:321–330.
- Hengeller C, Lancini G, Sensi P. 1973. 27-Demethoxy-27hydroxyrifamycin derivatives. US patent 3,743,635.
- Lal R, Lal S, Gründ E, Eichenlaub R. 1991. Construction of a hybrid plasmid capable of replication in *Amycolatopsis mediterranei*. Appl. Environ. Microbiol. 57:665–671.
- Khanna M, Dua M, Lal R. 1998. Selection of suitable marker genes for the development of cloning vectors and electroporation in different strains of *Amycolatopsis mediterranei*. Microbiol. Res. 153:205–211. http:// dx.doi.org/10.1016/S0944-5013(98)80002-5.
- Lal R, Khanna R, Dhingra N, Khanna M, Lal S. 1998. Development of an improved cloning vector and transformation system in *Amycolatopsis* mediterranei. J. Antibiot. 51:161–169. http://dx.doi.org/10.7164/antibiotics.51.161.
- Tuteja D, Dua M, Khanna R, Dhingra N, Khanna M, Kaur H, Saxena DM, Lal R. 2000. The importance of homologous recombination in the generation of large deletions in hybrid plasmids in *Amycolatopsis mediterranei*. Plasmid 43:1–11. http://dx.doi.org/10.1006/plas.1999.1426.
- Dhingra G, Kumari R, Bala S, Majumdar S, Malhotra S, Sharma P, Lal S, Cullum J, Lal R. 2003. Development of cloning vectors and transformation methods for *Amycolatopsis*. J. Ind. Microbiol. Biotechnol. 30: 195–204.

- 12. August PR, Tang L, Yoon YJ, Ning S, Müller R, Yu TW, Taylor M, Hoffmann D, Kim CG, Zhang X, Hutchinson CR, Floss HG. 1998. Biosynthesis of the ansamycin antibiotic rifamycin: deductions from the molecular analysis of the rif biosynthetic gene cluster of *Amycolatopsis mediterranei* S699. Chem. Biol. 5:69–79. http://dx.doi.org/10.1016/S1074 -5521(98)90141-7.
- 13. Schupp T, Toupet C, Engel N, Goff S. 1998. Cloning and sequence analysis of the putative Rifamycin polyketide synthase gene cluster from *Amycolatopsis mediterranei*. FEMS Microbiol. Lett. 159:201–207. http://dx.doi.org/10.1111/j.1574-6968.1998.tb12861.x.
- Kaur H, Cortes J, Leadlay P, Lal R. 2001. Cloning and partial characterization of the putative Rifamycin biosynthetic gene cluster from the actinomycete *Amycolatopsis mediterranei* DSM 46095. Microbiol. Res. 156: 239–246. http://dx.doi.org/10.1078/0944-5013-00108.
- 15. Zhao W, Zhong Y, Yuan H, Wang J, Zheng H, Wang Y, Cen X, Xu F, Bai J, Han X, Lu G, Zhu Y, Shao Z, Yan H, Li C, Peng N, Zhang Z, Zhang Y, Lin W, Fan Y, Qin Z, Hu Y, Zhu B, Wang S, Ding X, Zhao GP. 2010. Complete genome sequence of the Rifamycin SV-producing *Amycolatopsis mediterranei* U32 revealed its genetic characteristics in phylogeny and metabolism. Cell Res. 20:1096–1108. http://dx.doi.org/10.1038/cr.2010.87.
- Simpson JT, Wong K, Jackman SD, Schein JE, Jones SJ, Birol I. 2009. ABySS: a parallel assembler for short read sequence data. Genome Res. 19:1117–1123. http://dx.doi.org/10.1101/gr.089532.108.
- 17. Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formsma K, Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL, Overbeek RA, McNeil LK, Paarmann D, Paczian T, Parrello B, Pusch GD, Reich C, Stevens R, Vassieva O, Vonstein V, Wilke A, Zagnitko O. 2008. The RAST server: rapid annotations using subsystems technology. BMC Genomics 9:75. http://dx.doi.org/10.1186/1471-2164-9-75.
- 18. Blin K, Marnix H, Kazempour M, Fischbach MA, Breitling R, Takano E, Weber T. 2013. antiSMASH 2.0—a versatile platform for genome mining of secondary metabolite producers. Nucleic Acids Res. 41(W1): W204–W212. http://dx.doi.org/10.1093/nar/gkt449.
- Konstantinidis KT, Tiedje JM. 2005. Towards a genome-based taxonomy for prokaryotes. J. Bacteriol. 187:6258–6264. http://dx.doi.org/10.1128/ IB 187 18 6258-6264 2005.
- Nigam A, Almabruk KH, Saxena A, Yang J, Mukherjee U, Kaur H, Kohli P, Kumari R, Singh P, Zakharov LN, Singh Y, Mahmud T, Lal R. 2014. Modification of rifamycin polyketide backbone leads to improved drug activity against rifampicin-resistant *Mycobacterium tuberculosis*. J. Biol. Chem. 289:21142–21152. http://dx.doi.org/10.1074/jbc.M114.572636.